Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice. (scientific article published on January 2006)

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

Q28189095

Respiratory syncytial virus infection

Q33732334

Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease

Q35277282

Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada

Q35792916

Respiratory syncytial virus infection in children with congenital heart disease: a review

Q41004650

Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome

Q43673006

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

Q45710733

Substantial variability in community respiratory syncytial virus season timing

Q45710875

Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control

Q45740823

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

Q45759631

Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex.

Q45819313

Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience

Q45871994

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

congenital heart disease